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Perchlorate is used mainly in the manufacture
of solid propellants for rockets and missiles; it
is also used in ﬁreworks, road ﬂares, blasting
agents, and automobile air bags. Perchlorate is
highly water soluble and stable at ambient
temperature and pressure; it generally does not
adsorb to organic or inorganic materials.
Because of past disposal practices, extensive
contamination of surface water and groundwa-
ter by perchlorate has been reported in
California as well as other states. Recently, the
U.S. Food and Drug Administration (U.S.
FDA 2004) reported the detection of perchlo-
rate in lettuce and dairy milk samples.
Detections of perchlorate in lettuce, wheat,
tomato, cucumber, cantaloupe, dairy milk, and
human breast milk have also been reported by
others (Environmental Working Group 2002;
Jackson et al. 2005; Kirk et al. 2003, 2005;
Téllez et al. 2005).
Because perchlorate was not recognized as
an important environmental contaminant
until 1997, there are no established federal or
state regulatory standards. The California
Office of Environmental Health Hazard
Assessment (OEHHA) first released its draft
risk assessment on perchlorate for public com-
ment in March 2002. After extensive public
and scientific peer reviews, OEHHA’s final
risk assessment, “Public Health Goal for
Perchlorate in Drinking Water,” was published
in March 2004 (OEHHA 2004). In 2005 the
National Academy of Sciences (NAS 2005)
published its evaluation on the oral toxicity of
perchlorate. The New Jersey Drinking Water
Quality Institute (2005) and Massachusetts
Department of Environmental Protection
[Massachusetts DEP (2004b)] also released
their risk assessments on the chemical. In this
article we focus on the California efforts in
developing a health-protective drinking water
level for perchlorate, plus comments and dis-
cussion of more recent developments, which
provide a wider perspective.
Absorption and Toxicokinetics
of Perchlorate
Data from human and animal studies indicate
that perchlorate is readily absorbed from the
gastrointestinal tract and distributed systemi-
cally with total body water. A higher concentra-
tion of perchlorate is associated with the
thyroid than with other tissues. Perchlorate is
essentially unmetabolized in vivo (Wolff 1998).
When four patients were orally administered
200 mg of radiolabeled perchlorate (5 µCi),
double labeled with 36Cl and 18O, most per-
chlorate was excreted unchanged in the urine,
with the two labels (36Cl and 18O) remaining
associated in the same molecule (Anbar et al.
1959). Because the specific iodide transport
pump is present in the mammary gland, per-
chlorate is likely to be secreted into the breast
milk. According to a human study reported by
Greer et al. (2002) and an occupational study
reported by Lamm et al. (1999), the biological
half-life of perchlorate is approximately 8 hr.
Mode of Action
One of the most important biological effects
of perchlorate exposure at levels likely to be
encountered in the environment is the reduc-
tion of iodide uptake by the thyroid. Iodide is
actively transported via a transmembrane pro-
tein known as the sodium–iodide symporter
(NIS) into thyroid cells. Iodide is a key com-
ponent of thyroxine (T4) and triiodothyro-
nine (T3), hormones that are used to regulate
cell respiration, energy production, growth,
and maturation of body tissues. Perchlorate
competes with iodide for the NIS and at sufﬁ-
ciently high concentrations it can reduce or
even completely block the uptake of iodide into
thyroid cells. If there is a sustained decrease of
iodine supply to the thyroid, synthesis and
secretion of thyroid hormones can be impaired.
Levels of T4 and T3 in the blood are regu-
lated by a negative feedback mechanism that
helps the body to maintain hormone homeo-
stasis. When thyroid hormone levels in the cir-
culation are low, the hypothalamus stimulates
the pituitary through thyrotropin-releasing hor-
mone to produce thyroid-stimulating hormone
(TSH), which in turn prompts the thyroid to
produce more thyroid hormones. Prolonged
stimulation of the thyroid can lead to hyper-
trophy and hyperplasia of thyroid cells, which
can cause thyroid enlargement or goiter.
Iodine deﬁciency in pregnant women is a
health concern, as it can lead to impaired
growth and development in fetuses. The most
severe form of congenital hypothyroidism is
cretinism; less severe iodine deficiency can
reduce maternal serum thyroid hormone lev-
els and may subsequently impair fetal brain
development (Bleichrodt and Born 1994;
Glorieux et al. 1988; Haddow et al. 1999;
Pop et al. 1999, 2003; Rovet et al. 1987;
Tillotson et al. 1994; Vermiglio et al. 1990).
Animal Toxicity Data
In acute and subchronic animal studies, per-
chlorate administered through the oral route
(0.01–30 mg/kg/day) reduced uptake of iodide
into the thyroid, perturbed thyroid hormone
regulation, induced hypertrophy and hyperpla-
sia in thyroid cells, and caused an increase in
thyroid weight (Argus Research Laboratories
1998, 2001; Caldwell et al. 1995; Springborn
Laboratories 1998; Yu et al. 2000).
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in rats, perchlorate at doses up to 30 mg/kg/
day did not affect fertility and pregnancy out-
come measures. There were changes in thyroid
weight, thyroid histopathology, and thyroid
hormone levels in the dams or the offspring.
Some changes in the fetal brain development
were noted, but because of methodologic limi-
tations, the interpretation of the data is unclear
(Argus Research Laboratories 1998, 1999,
2001; Toxicology Excellence for Risk
Assessment, unpublished data, 2001). In a
two-generation rat study, two male pups in the
30-mg/kg/day dose group were found to have
thyroid follicular-cell adenomas (Argus
Research Laboratories 1999). Although the
result was not statistically signiﬁcant, it is note-
worthy because of the low historical back-
ground incidence rate of the tumor and the
relative short duration of exposure.
Ammonium perchlorate has been tested in
a battery of in vitro and in vivo genotoxicity
tests; perchlorate does not appear to be muta-
genic or clastogenic (OEHHA 2004). A num-
ber of animal studies have shown that
perchlorate at high doses (> 1,300 mg/kg/day)
causes thyroid tumors in rodents (Gauss 1972;
Kessler and Kruskemper 1966; Pajer and
Kalisnik 1991). Because the occurrence of the
tumors was preceded mostly by signs of thyroid
hormone disruption and thyroid enlargement,
these tumors are generally interpreted as being
secondary to the anti-thyroid effects of perchlo-
rate [OEHHA 2004; U.S. Environmental
Protection Agency (U.S. EPA) 2002].
Human Toxicity Data
In the 1960s, potassium perchlorate was used
to treat patients with Graves disease. The thera-
peutic dose ranged from 500 to 2,000 mg/day;
most of the treatments lasted several weeks, but
in a few cases treatment as long as a year was
reported (Crooks and Wayne 1960; Godley
and Stanbury 1954; Morgans and Trotter
1960). In some patients receiving high doses,
side effects such as skin rashes, nausea, gastro-
intestinal problems, and a serious blood
disorder were noted (Barzilai and Sheinfeld
1966; Fawcett and Clarke 1961; Hobson
1961; Johnson and Moore 1961). Crooks and
Wayne (1960) administered potassium per-
chlorate at 600–1,000 mg/day to a group of
pregnant women who were suffering from
hyperthyroidism and observed a slightly
enlarged thyroid in 1 of the 12 infants born to
the mothers. The enlarged thyroid returned to
normal size in 6 weeks, and no other abnor-
malities were observed.
Many occupational (Braverman et al. 2005;
Lamm et al. 1999) and ecologic studies
(Brechner et al. 2000; Crump et al. 2000; Kelsh
et al. 2003; Lamm and Doemland 1999; Li
et al. 2000a, 2000b, 2001; Morgan and
Cassady 2002; Schwartz 2001) investigated the
effects of perchlorate exposure on thyroid func-
tion. Although most studies were negative, two
studies showed a positive association (Brechner
et al. 2000; Schwartz 2001). Conﬁdence in the
positive results is not high because of the small
sample sizes, limited exposure data, and other
methodologic issues.
The negative results of other ecologic stud-
ies that investigated the association between
perchlorate in drinking water and abnormal
thyroid functions in adults and neonates have
also been questioned. Since the publication of
these studies, perchlorate has been detected in
lettuce and cow’s milk samples collected from
various states (U.S. FDA 2004). It shows that
perchlorate contamination is more widespread
than previously thought and that it is not lim-
ited to drinking water. Thus, the “unexposed
subjects” in the ecologic studies might also
have been exposed to perchlorate. The poten-
tial misclassification of perchlorate exposure
reduces the statistical power of, as well as the
conﬁdence in, the study results.
Many human studies have been con-
ducted. Stanbury and Wyngaarden (1952)
found that a single oral perchlorate dose as
low as 2.2 mg caused detectable release of
iodide from the thyroid and reported a posi-
tive correlation between perchlorate dose and
the fraction of stored iodide discharged from
the thyroid. At an oral dose of 900 mg/day
for 4 or more weeks, Brabant et al. (1992)
found that perchlorate caused a reduction of
iodide stored in the thyroid and thyroid
enlargement (U.S. EPA 2002), although there
were no increases in TSH levels.
Lawrence et al. (2000, 2001) and Greer
et al. (2002) administered perchlorate in
drinking water to adult volunteers for 14 days
and found a dose-related decrease in thyroidal
iodide uptake. No change in serum T4, T3, or
TSH levels was noted in all three studies.
Because the Greer et al. study was selected for
dose–response evaluation in our assessment, it
is described in greater detail. Groups of euthy-
roid male and female subjects were exposed to
perchlorate in water at 0.007, 0.02, 0.1, or
0.5 mg/kg for 14 days. The subjects were
asked to drink one-quarter of the perchlorate
dose at four time points spaced throughout
each day. Thyroid iodide uptake was meas-
ured before (baseline), during, and after the
14-day exposure period. They found a statisti-
cally signiﬁcant decrease in iodide uptake in all
except the lowest-dose group. There was no sex
difference. Uptakes measured on postexposure
day 15 were not significantly different from
the baseline, indicating the inhibitory effect of
perchlorate is reversible.
Hazard Identiﬁcation
Based on the toxicity information reviewed, the
most sensitive effect of perchlorate in humans is
the reduction of thyroidal iodide uptake (Greer
et al. 2002; Lawrence et al. 2000, 2001).
Depending on the severity and duration of
iodide uptake reduction, perchlorate can reduce
the amount of iodide stored in the thyroid
(Brabant et al. 1992) and cause thyroid enlarge-
ment (U.S. EPA 2002) in humans. At suffi-
ciently high doses, perchlorate can cause
histopathologic changes in the thyroid and
induce thyroid tumors in rodents.
Although perchlorate has been shown to
induce thyroid tumors in rodents, it is not
believed that it poses a signiﬁcant cancer risk to
humans. Perchlorate has not been shown to be
genotoxic. There is evidence that humans may
not be as sensitive quantitatively to thyroid
cancer from thyroid–pituitary disruption as
rodents (U.S. EPA 1998). Thyroid hormones
in rodents are not bound to T4-binding globu-
lin as in humans; they have a higher rate of
destruction and thus have to be replenished at
a higher rate. Rodent thyroid is chronically
stimulated and is more sensitive to chemicals
that disrupt thyroid hormone balance (Hill
et al. 1998).
Although there are limited human data on
the health consequences of chronic exposure to
perchlorate, health information related to
iodine deficiency indicates that pregnant
women and their fetuses are likely to be the
most sensitive to the anti-thyroid effects of per-
chlorate. Glinoer (2001) suggested that preg-
nancy itself represents a stress on the thyroid
hormonal system, and iodine deficiency can
compound the problem. Results of a prospec-
tive study reported by Kung et al. (2000)
showed that in a borderline iodine-sufﬁcient
area (median urinary iodine level = 9.8 µg/dL),
pregnancy resulted in higher rates of maternal
goitrogenesis as well as neonatal hypothyrox-
inemia and hyperthyrotrophinemia. It is
important to note that thyroid enlargement in
these women persisted and failed to revert
completely even 3 months after delivery.
Several epidemiologic studies indicate that
iodine deﬁciency during pregnancy may affect
brain development and cause neurointellectual
deﬁcits in the offspring. The severity of effects
depends on the timing as well as the severity of
iodine deficiency and thyroid disorder
(Morreale de Escobar et al. 2000). Evidence
suggests that normal fetal brain development
requires an adequate supply of maternal thy-
roid hormone throughout the ﬁrst trimester,
before the fetal thyroid begins to function
(Hollowell and Hannon 1997). Even border-
line maternal iodine deﬁciency, as observed in
some European countries, may be accompa-
nied by impaired school achievement in appar-
ently normal children (Glinoer 2001).
Dose–Response Evaluation
As discussed previously, the anti-thyroid effects
of perchlorate appear to be similar in rodents
and in humans. Quantitatively, however,
Ting et al.
882 VOLUME 114 | NUMBER 6 | June 2006 • Environmental Health Perspectivesrodents appear to be more sensitive. Several
14-day drinking water studies showed signiﬁ-
cant depression in serum T3 and T4 levels and
elevation in serum TSH levels in rodents
exposed to perchlorate doses as low as 0.01 or
0.1 mg/kg-day (Caldwell et al. 1995; Keil et al.
1998; Springborn Laboratories 1998; Yu et al.
2000). Similar human studies of the same
exposure duration showed no changes in serum
T3, T4, and TSH levels in volunteers exposed
to doses up to 0.5 mg/kg/day (Greer et al.
2002; Lawrence et al. 2000). After reviewing
the available toxicity studies, we considered
the thyroidal iodide uptake data reported by
Greer et al. (2002) to be the most appropriate
for quantitative dose–response evaluation. The
strengths of the study include both male and
female human subjects, four appropriately
spaced dose groups, a minimum of 7 subjects
per dose group with a total of 37 subjects, a
tightly controlled exposure regime, and thy-
roid function of the subjects measured before
and after the exposure. Limitations of the
study are short exposure duration and lack of
report of iodine status of the subjects during
the exposure.
Reduction of thyroidal iodide uptake was
identified as the critical end point instead of
changes in serum thyroid hormone levels or
serum TSH levels because a) iodide uptake
inhibition is a more clearly measurable phe-
nomenon and b) the 14-day exposure in the
Greer et al. (2002) study is an insufﬁcient time
to deplete thyroid iodine stores. Iodide-sufﬁ-
cient adults have enough iodide stored in the
thyroid to support normal thyroid function for
a few months. It is therefore not surprising that
even at the highest dose of 0.5 mg/kg/day with
> 65% reduction in iodide uptake, Greer et al.
did not observe any changes in serum T3, T4,
or TSH levels. Even at higher exposure levels, a
correlation between perchlorate exposure and
changes in serum T3, T4, or TSH levels may
not be demonstrable. In human studies, an
oral dose of 900 mg/day for 4 weeks had no
effect on serum T3, T4, or TSH levels despite
other adverse thyroid effects that were observed
(Brabant et al. 1992; U.S. EPA 2002).
Use of serum T3, T4, or TSH level as the
critical end point is also complicated by the
likely large interindividual variation in the
dose–response relationship. The perchlorate
exposure thresholds for changes of these hor-
mones are likely to depend on dietary iodide
intake level, amount of iodide stored in the
thyroid, preexisting stress on the thyroid,
exposure to other goitrogens, and age.
The decision to choose a perchlorate level
that does not reduce thyroidal iodide uptake
for risk assessment is considered health protec-
tive. Iodide uptake reduction is the ﬁrst step in
a chain of events that if severe and prolonged
can lead to changes in thyroid and pituitary
hormone levels, histopathologic changes of the
thyroid, and other adverse developmental
effects. It is believed that if perchlorate expo-
sure is kept at a level that does not affect iodide
uptake, then all the subsequent adverse health
effects can be prevented.
Another advantage of choosing inhibition of
thyroidal iodide uptake as the end point is that
it can minimize the effect of perchlorate on NIS
in nonthyroidal tissues. Besides the thyroid, NIS
has been found in stomach, lactating mammary
gland, and placenta and to a lower extent in
small intestine, skin, and brain (Perron et al.
2001). Because breast milk is the sole source of
nutrient for many infants, the potential of per-
chlorate to reduce the secretion of iodide into
the breast milk needs to be considered.
We employed the Benchmark Dose
Software (version 1.3.1; U.S. EPA 2000) to
perform the dose–response evaluation on the
data (Table 1) reported by Greer et al. (2002).
A benchmark dose (BMD) approach was used
because it uses all the data in the study, it is less
affected by the spacing of the doses, and it
accounts for the variability of the data as well as
the slope of the dose–response relationship. We
found that the Hill model adequately describes
the Greer et al. data (goodness of ﬁt test, p =
0.46), shown plotted in Figure 1. The model
was run with intercept set to zero, power para-
meter restricted to be greater than one, and the
assumption of a constant variance. The fit is
generally considered adequate when the p-value
is > 0.05. The form of the response function
estimated by the model is as follows:
Response = intercept + (v × dosen)/(kn + dosen), [1]
where intercept = 0, v = –73.4469, n = 1.15067,
and k= 0.0663651.
In choosing an appropriate benchmark
response level (BMR) for BMD modeling, we
consulted the U.S. EPA (2000) guideline and
determined that none of its suggestions are
applicable in this situation because it is not
obvious what level of thyroidal iodide uptake
reduction should be considered biologically
signiﬁcant or adverse, and there is no control
group in the Greer et al. (2002) study.
Instead, we experimented by setting the BMR
to a reduction of a) the mean standard devia-
tion (14%) of all the dosed groups in the
study, b) 10%, or c) 5%, and found that the
BMD corresponds to a calculated dose of
0.0188 mg/kg/day, 0.013 mg/kg/day, or
0.0068 mg/kg/day, respectively. Because the
calculated dose of 0.0188 mg/kg/day is close
to the second lowest dose (0.02 mg/kg/day) of
the study (Table 1), it can be considered to
give a positive response. The calculated dose of
0.0068 mg/kg/day is close to the lowest dose
(0.007 mg/kg/day) of the study (Table 1); it
can be considered to give a negative response.
Without additional data and not knowing the
standard deviation of the control group, it is dif-
ficult to determine if the calculated dose of
0.013 mg/kg/day (BMR = –10%) is a lowest
observed effect level (LOEL) or a no observed
effect level (NOEL). Given the options, we
decided to use –5% as the BMR and considered
it a NOEL. Using the parameters described, we
found that the BMD corresponds to 0.0068
mg/kg/day and that the lower limit of a one-
sided 95% conﬁdence interval on the BMD or
the lower confidence limit of the BMD
(BMDL) corresponds to 0.0037 mg/kg/day. In
the risk assessment, we used the BMDL as the
point of departure because it takes into consid-
eration the limited sample size of the study and
the variability exhibited in the data.
Development of a 
Health-Protective 
Drinking Water Level
Because pregnant women and their fetuses are
identiﬁed as the sensitive subgroups, we used
the following equation to estimate a health-
protective concentration for drinking water
(C, in milligrams per liter):
C = BMDL × RSC × (BW/WC) ÷ UF
= 0.0037 mg/kg/day × 0.6 × (25.2 kg/day/L) ÷ 10
= 0.0056 mg/L (rounded to 0.006 ppm, or 6 ppb),
[2]
where BMDL is the lower limit of a one-sided
95% conﬁdence interval of a perchlorate dose
that reduces mean thyroidal iodide uptake by
Drinking water level for perchlorate
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Table 1. Reduction of thyroid radioiodine uptake after a 14-day exposure to perchlorate.
Average dose Change in radioactive iodine uptake by the thyroid (%) No. of subjects
(mg/kg/day) after 24 hr of dosing (mean ± SD) in each dose group
0.007 –1.8 ± 22.0 7
0.02 –16.4 ± 12.8* 10
0.1 –44.7 ± 12.3* 10
0.5 –67.1 ± 12.1* 10
Data from Greer et al. (2002) and Goodman G (personal communication). 
*Statistically signiﬁcant, p < 0.005 (pairwise comparison with baseline).
Figure 1. Analysis of the Greer et al. (2002) data by
the BMD approach. Error bars represent the 95% CI
of the estimated mean.
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5%; RSC is the relative source contribution (a
value of 60% is used for pregnant women
because of the detection of perchlorate in farm
produce and cow’s milk); (BW/WC) is the ratio
of body weight (kilograms) and tap water con-
sumption rate (liters per day); the ratio for the
95th percentile of the pregnant woman popula-
tion is estimated to be 25.2 kg/day/L; OEHHA
2000); and UF is an uncertainty factor of 10 to
account for interindividual variability.
The water concentration resulting from this
calculation, 6 ppb, is judged adequate to pro-
tect all individuals, including potential sensitive
subpopulations, from adverse health effects of
perchlorate, from short-term to chronic expo-
sures. An uncertainty factor of 10 for interindi-
vidual variability is used because the subject
population in the Greer et al. (2002) study is
small (37 subjects) and did not include preg-
nant women, infants, or individuals with thy-
roid problems. Dietary iodine intake and
thyroidal iodide uptake are known to vary
among individuals; they are affected by the type
of food one eats (some food is rich in iodine,
whereas other foods contain goitrogens), smok-
ing habits (tobacco smoke contains goitrogens),
medication (e.g., lithium), and exposure to
environmental contaminants (e.g., nitrate, poly-
chlorinated biphenyls, and dioxins). The
interindividual variability in the general popula-
tion is likely to be greater than that shown by
the study population.
Preliminary survey results indicate that 
perchlorate is detected in lettuce, wheat,
tomato, cantaloupe, cucumber, and cow’s milk
(Jackson et al. 2005; Kirk et al. 2003; Sharp
2004; Smith and Jackson 2003; U.S. FDA
2004). Perchlorate has also been detected in
human breast milk samples (Kirk et al. 2005;
Téllez et al. 2005), thus conﬁrming the viabil-
ity of the breast milk exposure pathway as well
as indicating signiﬁcant neonatal exposures to
perchlorate from sources other than drinking
water. However, the data on food sources were
inadequate for a precise calculation of the con-
tribution of perchlorate from drinking water
versus food for pregnant women, the presumed
most sensitive population (with their fetuses).
On the basis of the available data, we assumed
that most of the perchlorate exposure would
come from drinking water and determined
that the most appropriate relative source
contribution is 60%.
Valentin-Blasini et al. (2005) analyzed
urine samples collected from 61 adults in an
area with no known perchlorate contamina-
tion (Atlanta, Georgia) and estimated that the
perchlorate in urine ranged from 0.66 to
21 ng/mL with a median level of 3.2 ng/mL
(7.8 µg perchlorate/g of creatinine). Because
the researchers found no perchlorate in the
area tap water, one can assume the perchlorate
in the urine was mainly derived from food or
sources other than drinking water. Based on
the public health goal (PHG) value of 6 ppb
(micrograms per liter) and a water exposure
measure of 25.2 kg/day/L (Equation 2), a per-
chlorate dose of 0.24 µg/kg/day from drinking
water exposure can be calculated. When this
dose estimate is combined with the median
estimate of 0.16 µg/kg/day provided by an
author of that study (Blount B, personal com-
munication), one obtains an RSC of 60% for
perchlorate from water. This rough calculation
supports the use of 60% as a reasonable esti-
mate of the RSC used in our risk assessment
(although the results of this study were made
available to us after our initial calculations).
An RSC of 20% from water (80% from other
sources, including food), the default recom-
mended by the U.S. EPA, would be more
applicable to average exposures, which are less
than 6 ppb, but was not representative of our
thinking in this case.
It has been suggested that an additional
uncertainty factor of 3 is needed to account
for the short exposure duration of the Greer
et al. (2002) study. However, there is evidence
that iodine uptake is inhibited very quickly
after exposure begins and that the inhibition
does not worsen as exposure continues. In
three of the dose groups, 0.02 mg/kg/day,
0.1 mg/kg/day, and 0.5 mg/kg/day, the 
degree of inhibition on day 2 was similar to
inhibition of day 14 (Greer et al. 2002).
Furthermore, it can be argued that if there is
no reduction in acute thyroidal iodide uptake,
there will be no reduction in stored iodide,
and extending the exposure duration is not
likely to affect thyroid function. For this rea-
son, we concluded that no additional factor is
necessary to account for the short exposure
duration of the study.
Discussion and Conclusion
In our human health risk assessment of
perchlorate, we identiﬁed the reduction of thy-
roidal iodide uptake as the critical end point. It
is reasoned that if this undesirable effect can be
avoided, then all the subsequent health effects
related to thyroid hormone disruption can be
prevented. We applied BMD modeling tech-
niques to a set of human data reported by
Greer et al. (2002) and determined a BMDL
(equivalent to a NOEL) of 0.0037 mg/kg/day.
Dividing by an uncertainty factor of 10 for
human variability, a health-protective daily dose
of 0.00037 mg/kg/day would be derived from
this exercise. A PHG of 6 ppb was calculated by
using the health-protective daily dose, a relative
source contribution of 60%, and exposure
assumptions speciﬁc to pregnant women.
Because the selected end point is related to
a physical property of a membrane protein,
the NIS, the interindividual variability is likely
to be less than that of changes in serum thy-
roid hormone or TSH level. The threshold of
the chosen end point is also less likely to be
affected by exposure duration, iodide status,
and the physiologic condition of the subject.
Given these considerations and the fact that
the critical end point was based on an early
effect in the chain of possible perchlorate
effects, derived from human studies, we con-
cluded that the uncertainty factor of 10 would
be adequate.
The recent analysis of perchlorate data by a
committee of the National Academy of
Sciences (NAS 2005) also used the data of
Greer et al. (2002) as a basis for its risk assess-
ment. The NAS committee assumed that the
lowest perchlorate dose (0.007 mg/kg/day) in
the Greer et al. study represented a NOEL for
iodide uptake inhibition and estimated a refer-
ence dose (RfD) by dividing this NOEL by an
uncertainty factor of 10, corresponding to an
equivalent dose of 0.0007 mg/kg/day. The
committee acknowledged the utility of BMD
modeling of the Greer et al. data but empha-
sized that there would be some difficulty
choosing among the various approaches
already published. Therefore it chose the
NOEL approach for its transparency. The
NAS committee did not proceed to estimate a
health-protective level of perchlorate in drink-
ing water from this RfD because this was not
one of the charges in its review. However, if a
health-protective level of perchlorate in drink-
ing water were estimated from this RfD using
the U.S. EPA default procedures, including a
default RSC of 0.2, the following equation
would result:
0.0007 mg/kg/day × 70 kg × 0.2 ÷ 2 L/day 
= 0.005 mg/L = 5 ppb. [3]
This result is essentially the same result as
that derived by our risk assessment approach,
although our use of the BMD method to deter-
mine a statistically more robust equivalent of
NOEL seems scientiﬁcally preferable. It is not
clear whether the U.S. EPA will use this
approach if it proceeds to establish a maximum
contaminant level goal for perchlorate in drink-
ing water. However, it should be noted that this
is the approach used by the State of New Jersey
in their newly proposed perchlorate rule (New
Jersey Drinking Water Quality Institute 2005).
A recent report by Ginsberg and Rice
(2005) criticized the NAS recommendation,
arguing that the lowest dose of the Greer et al.
(2002) study does not represent a NOEL. They
suggested that this dose should be treated as an
LOEL because four of the seven subjects in the
group showed a decrease in thyroidal iodide
uptake. Ginsberg and Rice also suggested that
perhaps the four subjects who appeared to
show a response to perchlorate constitute a
sensitive group because their thyroidal iodide
uptakes were consistently higher than the rest,
with or without perchlorate exposure. The
Massachusetts Department of Environmental
Protection interpreted these data in the sameDrinking water level for perchlorate
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way in their recent perchlorate risk assessment
(Massachusetts DEP 2004b). These factors, it is
argued, justify a much lower health-protective
standard. Looking at the Greer et al. data, we
ﬁnd it difﬁcult to say whether there are two dis-
tinct subgroups or whether the difference is just
a manifestation of normal interindividual vari-
ability. Because of the small number of subjects
and the relatively large variability observed in
the lowest-dose group, we decided not to use
the NOEL/LOEL approach for dose–response
characterization. Instead, we chose to use the
BMD approach. Doing so addresses these issues
and uses all the data in the study, not just those
in the lowest-dose group.
Use of iodide uptake inhibition as the criti-
cal end point for perchlorate risk assessment has
also been criticized for being too stringent. It
has been argued that reduction of iodine uptake
is not an adverse effect, but rather a precursor to
an adverse effect (Strawson et al. 2004). It has
been suggested that the highest dose in the
Greer et al. (2002) study should be identiﬁed as
the no observed adverse effect level (NOAEL)
instead because after 14 days of exposure at
0.5 mg/kg/day, no signiﬁcant changes in serum
T3, T4, or TSH levels were observed in the
exposed subjects. We disagree with this deter-
mination because even with a complete inhibi-
tion of thyroidal iodine uptake, the amount of
iodide stored in an iodine-replete adult can sus-
tain normal thyroid function for several months
(Greer et al. 2002). It is therefore likely that if
the perchlorate exposure at the 0.5 mg/kg/day
level were prolonged, there could be an impact
on the thyroid function. As pointed out previ-
ously, even under a controlled clinical situation
and at high exposure levels, it is not easy to
establish a relationship between serum T3, T4,
or TSH levels and perchlorate exposure
(Brabant et al. 1992). The thresholds for the
hormonal changes may be different for different
individuals because of variations in dietary
iodide intake, exposure to other goitrogens, age,
and physiologic conditions. Also, when an indi-
vidual suffers from a mild iodide deﬁciency, the
drop in serum T3 and T4 and the rise of serum
TSH are only transitory. These hormonal
changes make the thyroid function at a higher
level. When a new equilibrium is reached, the
serum T3, T4, and TSH levels return to nor-
mal. Indeed, the NAS committee stated that
under such conditions, thyroid enlargement
might be the only evidence that there had been
a change of serum thyroid hormones and TSH
at an earlier time (NAS 2005).
Strawson et al. (2004) argued that serum
T4 decrease is the critical effect of perchlorate,
which would be preferred for use in the risk
assessment. However, they acknowledge that
decreases in serum T4 have not been observed
in available human studies and that therefore
other approaches seem to be more useful.
Modeling the iodide uptake data of Greer
et al. (2002), Strawson et al. (2004) derived a
dose of 0.006 mg/kg/day based on a 10%
iodide uptake inhibition level. They compare
this dose with a “free-standing” NOAEL (the
highest exposure had no signiﬁcant effect) of
0.006 mg/kg/day in a human epidemiology
study of Chilean children (Crump et al. 2000).
Their conclusion is that, taken together, these
data deﬁne the potential effects in a sensitive
population quite well and justify the use of a
small uncertainty factor of 3. This results in an
RfD of 0.002 mg/kg/day. Using the same expo-
sure parameters as described in Equation 3, this
would result in a health-protective level in
drinking water of 14 ppb.
An opinion has been expressed that reduc-
tion of iodine uptake is not the best end point
for risk assessment because the effect is mun-
dane and can be caused by other chemicals
(Belzer RB, Bruce GM, Peterson MK, Pleus
RC, unpublished data, 2003; Bruce et al.
2005). Nitrate and thiocyanate also compete
with iodide for the NIS, and they are com-
monly found in food and the environment.
These chemicals are considerably less potent
than perchlorate as inhibitors of iodide uptake
(Lambers et al. 2000) but often occur at higher
concentrations. It is argued that it is unfair to
regulate perchlorate at a level that does not
cause reduction in thyroidal iodide uptake but
at the same time allow exposures to nitrate and
thiocyanate at levels where such an effect 
may occur. However, the presence of other
inhibitors in the environment increases the
need for vigilance against additional environ-
mental contaminants, and California law
requires consideration of the effects of multiple
chemicals that act similarly. Allocation of an
iodine-inhibition potential to chemicals con-
sumed in foods (which provide some beneﬁts)
might also be considered to take precedence
over pollutants consumed in drinking water.
OEHHA’s PHG has also been viewed as
not sufﬁciently health protective (Madsen and
Jahagirdar 2005; Massachusetts DEP 2004a).
It has been suggested that a larger uncertainty
factor should be used to account for the small
number of subjects in the lowest-dose group
of the Greer et al. (2002) study, the lack of
quality long-term exposure data, higher expo-
sure of infants and small children on a body-
weight basis, and special susceptibility of
infants’ brains to thyroid hormone disruption.
However, these opinions do not address the
fact that iodide uptake inhibition is not in and
of itself an adverse health effect. The daily
dose of perchlorate required to have an even-
tual effect on thyroid hormone production is
not well established but is certainly much
higher than the health-protective dose esti-
mated here, by the NAS (2005), or by
Strawson et al. (2004), largely on the basis of
prevention of iodide uptake inhibition. The
BMD modeling of the human iodide uptake
inhibition data of Greer et al. (2002) provides
an adequately health-protective end point. An
additional 10-fold uncertainty factor addresses
the limitations related to this study as well as
the existence of other goitrogens in the envi-
ronment. Based on our current understanding
of the toxicokinetics of perchlorate (Clewell
et al. 2003; U.S. EPA 2002), the internal per-
chlorate doses (expressed as area under the
curve of blood concentration) are similar in
infants and adults, at a given water con-
centration. This is because perchlorate is not
metabolized or retained by the body to any
significant extent, and the higher intake rate
(on a body-weight basis) of infants is likely to
be balanced by a higher excretion rate (on a
body-weight basis).
The approach described here makes the
best use of the available toxicologic data and
uses a reasonable approach in choosing a
health-protective level for perchlorate in drink-
ing water. By choosing a precursor effect to
deﬁne the point of departure in the risk assess-
ment, the risk assessment is likely to err on the
side of caution. This is partially offset by the
choice of a relatively small uncertainty factor.
Thus, we do not feel that the resulting recom-
mended health-protective level of 6 ppb per-
chlorate in drinking water is overprotective,
given the size of uncertainty factor chosen and
the various remaining uncertainties in the data.
As new information becomes available, the
health-protective level will be subject to revision
under California law.
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